Merck

BIopHarma
Employees:
14,600
Focus: Prescription drugs
of chemical and
biotechnological
origin

1.7 billion
invested in
Merck R&D
annually

Pipeline:
Approximately
20 programs
across
development

PHASE I

M2698
p70S6K & Akt inhibitor
Solid tumors

Global reach:
Products
commercialized
in 150
countries

M3814
DNA-PK inhibitor
Solid tumors
Beigene-283
BRAF inhibitor
Solid tumors
Avelumab1
Anti-PD-L1 mAb
Solid tumors

Manufacturing:
Biopharma
manufacturing
capabilities
across four
continents

Oncology, Neurodegenerative Diseases, Fertility,

Endocrinology and CardioMetabolic Care.

ACCELERATING INNOVATION IN OUR PIPELINE

Tepotinib
c-Met kinase inhibitor
Solid tumors

Global R&D Hubs:

Germany, US,
Japan, China

Portfolio of marketed products across

Pipeline products are under clinical investigation and have not been proven to be
safe and effective. There is no guarantee any product will be approved in the soughtafter indication.
President and CEO:
Beln Garijo

Headquarters:
Darmstadt,
Germany

OUR
MARKETED
PORTFOLIO

Therapeutic Areas:
Oncology, Immuno-Oncology,
Immunology, Neurodegenerative
Diseases, Fertility, Endocrinology,
General Medicine,
Cardiometabolic Care

M9241 (NHS-IL12)2
Cancer immunotherapy
Solid tumors

For more
information,
please visit
www.merckgroup.com

WE ARE MERCK
Merck is a leading company for innovative, top-quality high-tech products in healthcare,
life science and performance materials. Merck is the worlds oldest pharmaceutical and
chemical company since 1668, the company has stood for innovation, business success
and responsible entrepreneurship. Holding an approximately 70% interest, the founding
family remains the majority owner of the company to this day.

M7824 Bifunctional
immunotherapy
Solid tumors
M1095 (ALX-0761)
Anti-IL-17 A/F
nanobody
Psoriasis
M2951
BTK inhibitor
Systemic lupus
erythematosus

PHASE II

PHASE III

M2736 (ATX-MS-1467)
Immune tolerizing
agent
Multiple sclerosis

Avelumab1
Anti-PD-L1 mAb
Non-small cell lung cancer
1L3

Tepotinib
c-Met kinase inhibitor
Non-small cell lung cancer

Avelumab1
Anti-PD-L1 mAb
Non-small cell lung cancer
2L4

Tepotinib
c-Met kinase inhibitor
Hepatocellular cancer
Avelumab1
Anti-PD-L1 mAb
Merkel cell carcinoma
Sprifermin Fibroblast
growth factor 18
Osteoarthritis
Atacicept
Anti-Blys/anti-APRIL
fusion protein
Systemic lupus
erythematosus

PENDING SUBMISSION/
REVIEW

Cladribine Tablets6
Lymphocyte targeting
agent
Relapsing-remmitting
multiple sclerosis

Avelumab1
Anti-PD-L1 mAb
Gastric cancer 1L3
Avelumab1
Anti-PD-L1 mAb
Gastric cancer 3L5
Avelumab1
Anti-PD-L1 mAb
Bladder cancer 1L3
Avelumab1
Anti-PD-L1 mAb
Ovarian cancer platinum
resistant/refractory
Avelumab1
Anti-PD-L1 mAb
Renal cell carcinoma 1L3
MSB11022
Proposed biosimilar
of Adalimumab
Chronic Plaque Psoriasis

Neurodegenerative Diseases
Oncology
Immuno-Oncology
Immunology
Biosimilars

APRIL 2016

1. Avelumab is the anti-PD-L1 monoclonal antibody previously known as MSB 0010718C. 2. Sponsored by the National Cancer Institute (USA). 3. First Line treatment.
4. Second Line treatment. 5. Third Line treatment. 6. As announced on September 11th, 2015 Merck is preparing a regulatory submission to the European
Medicines Agency.

Merck Serono Australia Pty Ltd ABN 72 006 900 830. Units 3-4, 25 Frenchs Forest Road East, Frenchs Forest NSW 2086 Australia.
Phone +61 2 8977 4100. Toll Free 1800 633 463. AU-FER-0416-0003. 7/16.